S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:CBIO

Catalyst Biosciences - CBIO Stock Forecast, Price & News

$1.92
+0.06 (+3.23%)
(As of 08/12/2022 04:18 PM ET)
Add
Compare
Today's Range
$1.85
$1.93
50-Day Range
$1.17
$1.87
52-Week Range
$0.35
$5.20
Volume
195,995 shs
Average Volume
2.97 million shs
Market Capitalization
$60.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Catalyst Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
472.9% Upside
$11.00 Price Target
Short Interest
Healthy
5.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.38
Upright™ Environmental Score
News Sentiment
1.23mentions of Catalyst Biosciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.24) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

301st out of 1,117 stocks

Pharmaceutical Preparations Industry

144th out of 550 stocks

CBIO stock logo

About Catalyst Biosciences (NASDAQ:CBIO) Stock

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Catalyst Biosciences Trading Up 0.5 %

NASDAQ:CBIO opened at $1.86 on Friday. Catalyst Biosciences has a 12-month low of $0.35 and a 12-month high of $5.20. The stock has a 50-day moving average price of $1.65 and a 200 day moving average price of $0.99. The stock has a market capitalization of $58.55 million, a P/E ratio of -0.73 and a beta of 1.43.

Catalyst Biosciences (NASDAQ:CBIO - Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.10. Catalyst Biosciences had a negative return on equity of 149.54% and a negative net margin of 1,200.77%. The business had revenue of $0.79 million during the quarter. On average, research analysts predict that Catalyst Biosciences will post -1.24 earnings per share for the current fiscal year.

Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CBIO Stock News Headlines

Catalyst Biosciences Inc - Stock News
Catalyst Biosciences Sends Letter to Stockholders
Recap: Catalyst Biosciences Q1 Earnings
See More Headlines
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CBIO Company Calendar

Last Earnings
11/12/2021
Today
8/12/2022
Next Earnings (Estimated)
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CBIO
CUSIP
87611R30
Employees
56
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+472.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-87,930,000.00
Net Margins
-1,200.77%
Pretax Margin
-1,200.77%

Debt

Sales & Book Value

Annual Sales
$7.34 million
Book Value
$1.31 per share

Miscellaneous

Free Float
30,218,000
Market Cap
$60.44 million
Optionable
Optionable
Beta
1.43

Social Links


Key Executives

  • Dr. Nassim Usman Ph.D. (Age 62)
    Pres, CEO & Director
    Comp: $613.11k
  • Ms. Seline E. Miller CPA
    Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer
  • Dr. Grant Blouse M.Sc.
    Ph.D., Chief Scientific Officer
  • Dr. Howard Levy M.B.B.Ch. (Age 68)
    M.M.M., Ph.D., Consultant
    Comp: $434.21k
  • Ms. Ana Kapor
    Sr. Director of Investor Relations & Corp. Communications
  • Dr. Tom Knudsen D.V.M.
    Ph.D., Sr. VP of Corp. Devel.













CBIO Stock - Frequently Asked Questions

Should I buy or sell Catalyst Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBIO, but not buy additional shares or sell existing shares.
View CBIO analyst ratings
or view top-rated stocks.

What is Catalyst Biosciences' stock price forecast for 2022?

3 brokerages have issued twelve-month price targets for Catalyst Biosciences' shares. Their CBIO share price forecasts range from $4.00 to $18.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 478.9% from the stock's current price.
View analysts price targets for CBIO
or view top-rated stocks among Wall Street analysts.

How have CBIO shares performed in 2022?

Catalyst Biosciences' stock was trading at $0.9140 at the beginning of 2022. Since then, CBIO stock has increased by 107.9% and is now trading at $1.90.
View the best growth stocks for 2022 here
.

When is Catalyst Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our CBIO earnings forecast
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $0.14. The biopharmaceutical company earned $2.30 million during the quarter, compared to analyst estimates of $1 million. Catalyst Biosciences had a negative net margin of 1,200.77% and a negative trailing twelve-month return on equity of 149.54%.

When did Catalyst Biosciences' stock split?

Catalyst Biosciences shares reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Celsion (CLSN).

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

How do I buy shares of Catalyst Biosciences?

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $1.90.

How much money does Catalyst Biosciences make?

Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $59.81 million and generates $7.34 million in revenue each year. The biopharmaceutical company earns $-87,930,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis.

When was Catalyst Biosciences founded?

Catalyst Biosciences was founded in 2003.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107.

This page (NASDAQ:CBIO) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.